• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

ESMO: GSK keeps the faith in anti-TIGIT plans; it's 'not always about being...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 09, 2022 at 12:12: PM
via Four months after the latest trial failure for Roche’s tiragolumab, GSK is still pushing ahead with its own anti-TIGIT inhibitor, bullish that plenty of opportunities remain for the next-gen therapy.

article source
 




Top Bottom
Back
Quote